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Summary
Parkinson's disease is a chronic disabling condition with specific histopathological findings. No cure is
yet available although treatment response can be remarkable. Family physicians are often faced with
problematic issues on diagnosis and therapy when managing patients with Parkinson's disease. Levodopa is
still the mainstay of treatment but its long-term use can be associated with considerable side-effects. We
advocate the use of dopamine agonists as de novo therapy in younger onset patients. The application of
stereotactic functional surgery has great potential in the treatment of Parkinson's disease. (HK Pract
1998;20:20-32)
Introduction
The prevalence of Parkinson's
disease (PD) is about 1 in 800,
representing a patient load of almost
8000 in Hong Kong. PD is a chronic
neuro-degenerative disease and no cure
has yet been found. The cause is not
known. We present an overview on the
diagnostic and therapeutic issues that
family physicians have to face in the
day-to-day management of patients
with PD. Some novel therapeutic
approaches, in particular stereotactic
functional surgery, are discussed.
Diagnosing Parkinson's
disease
The cardinal signs of PD are
rigidity, bradykinesia, tremor, and
postural abnormalities. All these
features are usually, but not always,
present. The presence of upper body
bradykinesia is essential for diagnosis.1
The typical rest tremor is described as
pill-rolling, with a frequency of 3-6 Hz.
Postural instability, falls, and freezing
tend to be late features. Early
symptoms, such as muscle ache, fatigue,
and constipation, are vague and non-
specific and can therefore be easily
overlooked.
(Continued on page 22)
Address for correspondence: Dr S L Ho, Associate Professor, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.
20
management of Parkinson's Disease
Dementia is not a feature of PD
until the late stage. However, patients
with PD may develop a subcortical type
of cognitive impairment, characterised
by apathy, slowness of thought, lack of
motivation and, blunting of drive.
The gold standard for the diagnosis
of PD relies on histopathological
findings with the typical features of
substant ia nigra pars compacta
degeneration (Figure 1) and loss of
pigmentation, and the presence of
intraneuronal Lewy bodies (Figure 2).
Clinical examination may not be
entirely reliable in differentiating PD
from other parkinsonian syndromes. Up
to 1/4 of cases diagnosed clinically as
PD by neurologists turned up to be
incorrect at post-mortem examination.2'3
Although PD is the commonest
cause of parkinsonism, other causes
ought to be considered (Table 1).
Dopamine antagonistic drugs, such as
neuroleptics, antihistamines, prochlop-
erazine, and metoclopramide, can
induce secondary parkinsonism and
very often exacerbate parkinsonian
features in PD. Vascular pseudo-
p a r k i n s o n i s m due to cerebral
atherosclerosis usually shows a different
pattern of involvement from PD. Their
gait and postural stability are more
affected than the upper limb functions.
In diffuse Lewy body disease, early
dementia is a prominent feature.
Wilson's disease must be excluded in
early-onset PD. The "parkinsonian
syndromes" include multiple system
atrophy (MSA) and progressive
supranuclear palsy (PSP). Their initial
presentation may be similar to PD.
In MSA, neuronal loss and gliosis
without Lewy bodies occur in a
Figure 1: Transaxial section across the mid-brain of a patient with
Parkinson's disease showing unilateral substantia nigra
depigmentation
Figure 2: Inclusional Lewy body (arrow) forming a halo appearance
within a neuromelanin-containing neuron
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multiplicity of other structures, e.g.
substantia nigra, globus pallidus,
i n f e r i o r o l i v e s , c e r e b e l l u m ,
corticospinal tract, etc. Almost all the
patients have parkinsonian features and
autonomic dysfunction. The typical
parkinsonian pill-rolling tremor is
exceedingly rare in MSA. Cerebellar
and pyramidal features are present in up
to 35% and 60% of patients with MSA
respectively.4-5 There are several clinical
subtypes classified according to the
predominant impairment in addition to
the parkinsonian features:
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1) Shy-Drager syndrome presents
with autonomic failure,
2) Striatonigral degeneration presents
with pyramidal spasticity, and
3) Olivoponto-cerebellar degenera-
tion presents with cerebellar ataxia.
Median age of onset is 53 to 55
and the median survival is 7.3 to 7.5
years.5-6 However, early disability is
common with over 40% of patients
becoming non-ambulatory five years
after the onset of motor symptoms.5
PSP, also known as Steele-
Richardson-Olszewski Disease, is an
akinetic-rigidity predominant parkinso-
nian syndrome characterized by early
postural instability and falls, axial
rigidity, bulbar dysfunction, and a
prefrontal-type of dementia.7 8 The
classical sign is a limited downward
gaze. The median age of onset is 63 and
the median survival is 5.6 years.7
Assessing adopaminergic respon-
siveness to levodopa is use fu l in
d i f f e r e n t i a t i n g PD f rom other
parkinsonian syndromes. Over 70% of
PD have excellent response to levodopa.
Failure to respond suggests, but does
not confirm, an alternative diagnosis.
Diffuse Lewy body disease also respond
to levodopa but prominent visual
hallucinations and psychosis are often
precipitated. Vascu la r pseudo-
parkinsonism is typically refractory to
levodopa.9 Only 50% of MSA10 and
38% of PSP11 improve with levodopa,
but usually with moderate and transient
response. Facial and neck dystonias are
commonly induced. Apomorphine
given subcutaneously can be used as an
indicator of dopaminergic respon-
siveness.12
Reduced putaminal 18F-Dopa
u p t a k e o n p o s i t r o n e m i s s i o n
tomography (PET)13 is a specific finding
in PD. S ingle -photon emission
computerised tomography (SPECT)
with iodine-123 labelled B-CIT,14
iodobenzamide,15 and iodo-lisuride16
are also useful in detecting early cases
of PD and quantifying the disease
severity. However, the application of
these techniques is often limited to
research centres.
For practical considerations, a
diagnosis of idiopathic PD is unlikely if
dementia, postural instability and falls
occur at an early stage, and cases which
are refractory to treatment. Features
agains t a d iagnos is of PD are
summarised in Table 2.
Table 1: Differential diagnosis of Parkinsonism
1) Parkinson's disease (Idiopathic Parkinsonism)
2) Secondary (symptomatic) Parkinsonism
Postencephalitic - encephalitis lethargica
Drug-induced - neuroleptics, anti-emetics (prochlorperazine,
metoclopramide), anti-histamines
Toxic - copper (Wilson's disease), carbon monoxide,
manganese, MPTP
Traumatic - "Punch-drunk" syndrome
3) Multiple system atrophy
4) Progressive supranuclear palsy
5) Lewy body dementia
6) Corticobasal degeneration
7) Pseudoparkinsonism - atherosclerosis, "normal-pressure" hydrocephalus
1. Modest to poor response to levodopa / apomorphine
2. Rapid deterioration
3. Early dementia
4. Early falls
5. Prominent autonomic symptoms
6. Gaze palsy
7. Cerebellar signs
8. Pyramidal signs
(Continued on page 25)
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Pharmacotherapy
Therapeutic approaches to PD are
subjected to many controversies, in
particular, whether treatment could
influence its progression. As far as
pharmacotherapy is concerned, there are
two categories of treatment to be
considered:
1. Neuroprotection
At present, there is no conclusive
evidence that progression of PD
can be delayed. Tocopherol
(vitamin E) was shown to be
ineffective in neuroprotection.17
The role of monoamine-oxidase B
(MAO-B) inh ib i to r s is stil l
controversial.l8-19
2. Symptomatic Treatment
The objective is to maintain
independent functioning for as
long as possible.
Levodopa
Levodopa is the mainstay and most
potent drug for treating PD. The
features of PD manifest when 60-80%
of nigrostriatal neurons are degenerated
with 90% reduction of s t r ia ta l
dopamine. Levodopa enters the
striatum and is converted into dopamine
by 1-aromatic amino acid decarboxylase
and replenishes the deficient store.
Levodopa is combined with a
dopa-decarboxylase inhibitor (DDI) to
minimise its peripheral dopaminergic
side-effects and increase its concentra-
tion in the central nervous system. The
DDI in Sinemet and Madopar are
carbidopa and benserazide respectively.
Levodopa should be introduced slowly
with dose incrementations every six to
twelve weeks depending on the clinical
response.
In the initial stage of PD, a stable
reversal of almost all its manifestations
can be obtained with levodopa. This is
the therapeutic "honeymoon period".
Exogenous dopamine source can
generate a storage in the remaining
nigral neurons that is sufficient to
maintain a steady supply to the striatal
receptors. The g r adua l loss of
dopaminergic terminals diminishes the
capability to synthesize, store, release
and reuptake dopamine.
After some years of levodopa
treatment, a significant proportion of
patients will develop complications,
which represent a complex interaction
between the long-term drug effects and
disease progression. Motor fluctuations
are major problems in younger patients,
and neuro-psychiatric symptoms tend to
occur in elderly patients.
Since the introduction of levodopa,
several unique treatment-related motor
fluctuations were recognized,20 which
develops in approximately 50% of
patients after five years of treatment. A
"benign" pattern of predictable
oscillations with end-of-dose wearing-
off usually progresses to the more
"malignant" random swings. This
picture is further complicated by the
occurrence of dyskinesia.21
With long-term levodopa, a
therapeutic threshold gradually emerges
with an all-or-none clinical response
across a certain levodopa level. Above
this threshold, the patient remains more
or less responsive and increasing the
dosage will not improve the quality of
therapeutic response. The threshold
persists and remains almost unchanged
during chronic levodopa treatment.
This finding can be explained by the
fo l lowing mechanism. Disease
progression results in a reduction of
presynaptic dopamine storage terminals
so that the ability to buffer fluctuations
in levodopa level is lost. Besides the
striatum, uptake and conversion of
levodopa to dopamine also take place in
the endothel ia l and gl ial cells.
However, these extra-striatal sites lack
the appropriate control of storage and
release of dopamine. Their contribution
increases as more neurons in the
substantia nigra degenerate, so that
dopamine is released intermittently and
in large quantity as soon as they are
synthesized from their substrate. The
synaptic dopamine concentration is
therefore directly dependent on the
availability of levodopa. Clinically, the
patient will experience a predictable
response soon after a dose of levodopa,
but will deteriorate towards the end of
it when the drug level is below
therapeutic threshold. The first
symptom is usually early morning
akinesia. Later, tremor and bradykinesia
occur regularly in a close temporal
periodicity to the timing of levodopa
dosage.
In at least 15% of levodopa-treated
patients, motor fluctuations become
increasingly abrupt, with sudden and
unpredictable off periods. The off-
period can be compl ica ted by
distressing positive symptoms, such as
dystonia, sensory, autonomic and
psychiatric symptoms. Dose failure is
an advanced stage of response
f l u c t u a t i o n when one or more
25
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succeeding doses do not reverse the
parkinsonian symptoms. The exact
mechanism for these unpredictable
swings is unknown. They may be due
to pharmacodynamic changes which
lead to altered interactions between
dopamine and the striatal receptors.
Relatively small fluctuations in cerebral
levodopa and dopamine concentrations
may have a large effect on drug
response. Peripheral pharmacokinetic
factors may also contribute to these
swings.
Dyskinesia can be classified into:
1) Peak-dose dyskinesia, which is
often choreic and ballistic,
2) Low-dose dyskinesia, which is
typically dystonic and painful, and
3) Diphasic dyskinesia, with mixed
pattern of chorea, ballismus and
dystonia.
The occurrence of dyskinesia is
due to a complex interaction between
the fluctuating striatal dopamine level
and its differential stimulation on the
subtypes of receptors, including
agonist ic and antagonis t ic , that
d i s t r i b u t e s a b n o r m a l l y in the
degenerating striatal pathways.
To manage peak-dose dyskinesia,
frequent administration of levodopa is
only effective initially. The small,
frequent dosage may not achieve a
therapeutic level to produce a clinical
response. Moreover, the duration of
response is reduced. During chronic
levodopa therapy, the threshold for
production of peak-dose dyskinesia
decreases, sometimes to below the
therapeutic threshold. The therapeutic
window of levodopa thus narrows to a
state when motor response always
coexist with dyskinesia. For some
patients, peak-dose dyskinesia may not
cause significant functional disability
despite its alarming clinical appearance.
Dose reduction improves dyskinesia
o n l y at the expense of motor
deterioration, which is often more
disabling.
A third of chronic levodopa users
deve lop p a i n f u l d y s t o n i a as a
manifestation of low-dose dyskinesia.
Withholding levodopa will eventually
lead to its cessation. However, drug
holiday of levodopa is no longer
recommended since a fatal neuroleptic
mal ignant - l ike syndrome can be
precipitated. The addition of muscle
relaxants and anticholinergics can
sometimes be helpful in painful
dystonia.
Diphasic dyskinesia is linked to a
critical levodopa plasma level and
emerges at the transition between
rising and falling phases of drug
concentration. The typical pattern is
dyskinesia-improvement-dyskinesia
(D-I-D). Management is difficult.
Patients may remain in a continuous
dyskinetic state if only an intermediate
levodopa level is achieved. Frequent
high doses of levodopa which exceed
the therapeutic threshold are needed to
overcome this problem.
Motor f luc tua t ions form an
additional disability which goes beyond
that of the original disease. It was
postulated that the large-amplitude,
unphysiological swings in levodopa
levels produced by conventional therapy
c o n t r i b u t e to these long- te rm
complications by inducing postsynaptic
dopamine receptor hypersensitivity.
The maintenance of stable peripheral
and central levodopa concentration may,
therefore, be important in reducing
motor fluctuations. There are several
strategies to achieve a constant
levodopa level.
Differential actions of intermittent
levodopa on dopaminergic receptor
subtypes lead to downregulation of the
direct pathway and upregulation of the
indirect pathway. This imbalance
results in dyskinesia. Continuous
duodenal levodopa infusion22-23 that
avoids drug level oscillations had been
shown to restore this balance. However,
l ong- t e rm i n f u s i o n t he rapy i s
impractical as well as uncomfortable
for the patients.
Controlled-release del ivery
systems of levodopa (Sinemet CR,
Madopar HBS) aim at modifying the
pharmacokinetic profile by producing a
more steady drug level. The peak
levodopa level is brought down by
about 1/3 and the trough level is
approximately doubled. The bio-
availability of levodopa is reduced by
about 25% with these preparations and
the total levodopa dosage has to be
increased accordingly. In the short-
term, motor fluctuations and dose
frequency can often be reduced. Some
patients may find it troublesome when
they switch from conventional to
controlled-release preparations because
the onset of clinical effect can be
delayed for over one hour. Supplements
of conventional levodopa is often
required.
Protein in food and neutral amino
acids in blood compete for carrier
system with levodopa.24 Protein
reduction or redistribution may increase
the efficacy of oral levodopa by
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achieving a favourable balance of
absorption and transport. In advanced
PD, gastric emptying can be an
important rate-limiting step in levodopa
absorption.25 Prokinetic agents without
dopamine antagonistic properties, such
as domperidone and cisapride, are
useful both for improving drug
absorption and alleviating drug-induced
emesis by promoting gastric emptying.
Levodopa-induced cognitive and
neuropsychiatric problems are common
in the elderly patients. They typically
describe faces and figures on the wall.
Insight is often preserved and the
hallucinations can be well-tolerated.
Sometimes, more sinister hallucinations
and ful l -blown psychosis can be
precipitated. Mental symptoms will
respond to reduction of levodopa dosage
at the expense of motor deterioration. If
it is not possible to reduce the levodopa
dosage, c lozapine , an a typ i ca l
neuroleptic with low propensity for
inducing extrapyramidal side-effects,
can be added. Clozapine also exerts a
dose-related suppression of levodopa-
induced dyskinesia26. However, fatal
agranulocytosis had been reported in
association with clozapine so that close
haematological monitoring under
specialist supervision is required when
this drug is prescribed. The dose of
Clozapine should be increased
gradually as patients may develop
tiredness and increased salivation.
The dosage required to settle drug-
induced psychosis in PD is usually
much less than that needed for
schizophrenia.
It has been postulated that the
unphysiological dopaminergic response
from levodopa therapy might form a
source of oxidative stress in the central
nervous system. Up till now, there is no
firm evidence that levodopa can
accelerate neuronal death in human.
However, we know that levodopa
benefits patients with PD by extending
their life-expectancy and improving
their quality of life.27'28
Dopamine Agonists
Dopamine receptors can be
classif ied by their t r ansduc t ion
mechanism into either Dl- like (Dl &
D5) and D2 like (D2, D3 & D4).
Bromocr ip t ine and pramipexole
stimulate Dl- and D2- like receptors
respectively, while pergolide stimulates
both. A combination of Dl- and D2-
like receptors activation might be of
greater benefit in preventing motor
fluctuations and dyskinesia than
activation of individual receptors
alone.
Using dopamine agonists as
monotherapy may provide adequate
therapeutic effect especially in young-
onset cases. Progression of disability
may be delayed for over two years.29
Their long half-life may prolong the
therapeutic response of levodopa and
reduce the associated motor fluctuations
and dyskinesia. Their long-term role
in delaying motor fluctuations is
unknown. The dosage should be
gradually increased. A rapid increase
in dosage results in side-effects such
as nausea, vomiting, and postural
hypotension. The levodopa dosage
may be reduced after introduction of
dopamine agonists.
Apomorphine is a potent non-ergot
derivative dopaminergic Dl and D2
agonist. The development of new
delivery systems permits a reintro-
duction for future practical usage. It is
effective in reversing end-of-dose
wearing-offs and the associated non-
motor positive symptoms. A reliable
response begins 5 to 15 minutes after
subcutaneous injection and lasts for a
mean of 60 minutes. In general, 1 to
3 mg is given two to six times a day.
Alternatively a continuous subcutaneous
infusion mini-pump can be used.
Apomorphine is especially indicated in
pat ients with predictable motor
fluctuations and who are capable of
anticipating their onset with a booster
dose. The therapeutic benefits of
apomorphine can be maintained for
more than five years.30 Prophylactic
domperidone is necessary to prevent
nausea, which will wear off after several
months as tolerance to the peripheral
effects of apomorphine develops.
Anticholinergic drugs
These agents work by blocking the
striatal muscarinic receptors to reduce
excessive cholinergic activity. Anticho-
linergic drugs are more useful for
parkinsonian tremor than rigidity or
akinesia. In mild PD, anticholinergics
can be used as sole therapy with 20%
functional improvement. In more
advanced disease, they are useful for
levodopa-induced dystonia. Their use
in the elderly is limited by their side-
effects, which are related to their
antimuscarinic properties. Faecal
impaction, urinary retention, and acute
glaucoma can be precipitated. Elderly
patients are particularly prone to drug-
induced hallucination and confusion31
and hence should be used with caution
in the elderly. Anticholinergic agents
should be tapered very slowly since
abrupt withdrawal can result in acute
deterioration of parkinsonism.
(Continued on page 30)
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Monoamine-oxidase B inhibitors
MAO-B is responsible for 80% of
the striatal MAO activities involved in
the breakdown of dopamine. Selegiline
(L-deprenyl, Jumex) at doses below
20 mg/day inhibits MAO-B selectively.
It is given twice daily in the morning
and at noon. Evening doses may
precipitate insomnia and nightmare.
There is no definite evidence that
progression of disease can be delayed
with selegiline.
Amantidine
Presynap t ica l ly , a m a n t i d i n e
enhances release of stored dopamine
and inhibit its reuptake. Postsynapti-
cally, it increases the affinity of
dopamine receptors. Its efficacy is
similar to that of the anticholinergics.
The recently demonstrated N-methyl-4-
D-aspartate (NMDA) antagonistic
property of amantidine has renewed its
clinical interest as a potential neuro-
protective agent in the glutamate
pathway.
Cathechol-0-methyl-transferase
inhibitors
Cathechol-O-methyl-transferase
(COMT) is involved in the methylation
of levodopa to 3-0-methyldopa, and
dopamine to 3-methotyramine. By
blocking these two pathways with
COMT-inhibitors, the level of dopamine
in the s t r ia tum can be increased.
Moreover, 3-0-methyldopa competes
with levodopa for cerebral uptake and
may also antagonise the action of
levodopa and dopamine. Entacapone
acts peripherally. Tolcapone exerts an
additional effect at the synaptic level by
penetrating the blood-brain barrier.
Initial studies of COMT inhibitors have
shown their efficacy as adjunctive
therapy to levodopa.32,33
L-threo-dihydroxyphenylserine
Progression of disease will cause
more gait instability and freezing
episodes. These manifestations are
related to noradrenergic or serotonergic
pathways rather than the dopaminergic
system, so that conventional agents are
less effective. L-threo-dihydroxyphe-
nylserine (L-DOPS), which increases
cerebral noradrenaline, has been used
for specific treatment of freezing
episodes.
Role of family physicians in
managing Parkinson's
disease
Patient counseling is an essential
part of managing PD including the
discussion of disease prognosis,
t reatment options and potential
complications. It should be emphasised
that although PD cannot be cured,
effective treatment is available and life
expectancy can be close to normal.
There is no consensus on the best
treatment plan for PD. Generally
speaking, anti-parkinsonian therapy
needs to be individualised to the
specific patient. The trend is to use
dopamine agonist and withhold
levodopa at the start of treatment in
younger-onset patients3435 unless their
side-effects are intolerable. In the early
stages of the disease, anticholinergics,
selegiline and dopamine agonists may
be sufficient for many months, although
their efficacy is much less than
levodopa. We generally use the
controlled-release rather than
conventional preparations when
levodopa therapy is initiated.
A shared-care approach with
neurologists is indicated for young onset
patients, those with atypical features,
and when control of the disease
becomes difficult.
Patients with a younger age of
disease onset have a slower progression
of disease, better initial levodopa
response, but earlier and more frequent
response fluctuations.36 They have
many years of disease and treatment
ahead, m a k i n g the balance of
therapeutic decisions much more
difficult. It is our practice to introduce
dopamine agonists as initial therapy for
patients whose age of onset is below 60.
Surgical treatment
Fetal mesencephalon transplantation
Replacement of dopamine-
producing cells with fetal mesen-
cephalon grafts is still undergoing
experimental assessment. Many
questions about the techniques remain
unanswered, including the optimal
amount of fetal tissue needed, the
best site for implantation, and the
requirement for immunosuppressants.
Stereotactic functional neurosurgery
With the advent of high resolution
neuro-imaging devices and more precise
30
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Table 3: Stereotactic neurosurgery -therapeutic effects
••••• •••••••• •••*••• *•••••• IMBBBM
Lesioning procedures :
Deep brain stimulation:
Tremor
Rigidity
Akinesia, gait
Dyskinesia
Off-period dystonia
Thalamotomy
Vim
+ + +
+
0
+
0
Pallidotomy
GPi STN
+ + + + -t-
+ + + + +
+ + + +
+ + + +
+ + + + +
Vim - ventralis intermedius
GPi - globus pallidus internus
STN - subthalamic nucleus
O - no response; + + + - maximum response
localising techniques, stereotactic
functional neurosurgery with high levels
of precision can now be carried out.
Generally, surgery for PD involves three
main steps. Firstly, the anatomical
target is defined stereotactically with
neuro-imaging techniques. Then,
electrophysiological assessment is
per formed by the i n s e r t i o n of
stereotactic intracranial probes to
identify the target nucleus and avoid
nearby structures. The final step is
thermolytic lesioning of the target or
implantation of deep brain stimulating
electrodes. The stimulating electrodes
are connected to a programmable pulse
generator w h i c h is placed in a
subcutaneous pocket under the clavicle
like a cardiac pace-maker. Stimulating
variables can be altered by an external
programming.
Thalamotomy is an ablat ive
technique for control of tremor but does
not ease bradykinesia or rigidity.
Pallidotomy is helpful in ameliorating
all cardinal features of PD as well as
levodopa-induced dyskinesia, and was
shown to produce favourable functional
ou tcomes . 3 7 ' 3 8 The e f f e c t s of
thalamotomy and pallidotomy are
predominantly on the contralateral side
so that symptoms in patients with
generalised disease cannot be totally
abol ished. Bi la tera l l es ion ing
procedures are rarely performed because
of the significant side-effects including
speech and cognitive impairment.
Recent advances have been made
in deep brain stimulation (DBS) of
various target nuclei. The exact
mechanism of action of DBS is still not
entirely understood. The effects of DBS
are immediate and reversible when the
stimulation stops. Stimulation of the
ventral intermediate (Vim) thalamic
nucleus abolishes tremor39 while
stimulation of the subthalamic nucleus
(STN) or globus pallidus intemus (GPi)
improves all cardinal features of PD.40
DBS can be performed bilaterally or
combined wi th various lesioning
techniques.
These stereotactic procedures,
particularly DBS, are highly promising
in improving the quality of life of
patients with advanced PD. Their
therapeutic effects are summarised in
Table 3. •
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